₹973.35
₹-65.20 (-6.28%)
Closed · As of 26 Aug 3:30 pm
Mkt Cap
₹5,819 Cr
P/E
542.88
ROE
1.34%
ROCE
1.62%
About Orchid Pharma Ltd
Orchid Pharma 01 the leading ptlarrna<;eutlcal oompanies in India haad quartered In Channai and Involved in the davelopment, manufacture and marketing of diverse bulk aeWes. formulationS and nutraceu~cals with exports spanning over 40 counllies. Orcttid's world class manufacturing infrasl1uclure Include USFDA compliant API and Finished Dosage Form faciliUes at Chennai In India. OrctIid lias dediCilted stale-of-art and GLP compliant R&D infrastructure fOf Procen researetl, Drug Discovery and Pllarmaceut!cal researen at Chennal, India.
Founded
1992
CEO
R G Agarwal
Employees
1,051
HQ
Chennai, Tamil Nadu
About Orchid Pharma Ltd
Orchid Pharma 01 the leading ptlarrna<;eutlcal oompanies in India haad quartered In Channai and Involved in the davelopment, manufacture and marketing of diverse bulk aeWes. formulationS and nutraceu~cals with exports spanning over 40 counllies. Orcttid's world class manufacturing infrasl1uclure Include USFDA compliant API and Finished Dosage Form faciliUes at Chennai In India. OrctIid lias dediCilted stale-of-art and GLP compliant R&D infrastructure fOf Procen researetl, Drug Discovery and Pllarmaceut!cal researen at Chennal, India.
Founded:1992
CEO:R G Agarwal
Employees:1,051
HQ:Chennai, Tamil Nadu
Finished Products
1Sale of Products
₹1,724.26Cr2Cephalosporin API
₹1,202.08Cr3Other Operating Revenue
₹17.40Cr4Cephalosporin FDF
₹5.50Cr5Sale of other material
₹3.73Cr6Other Sales
₹2.95Cr7Sales
₹2.81Cr1–7 of 10
Raw Materials
1Cost of Materials Consumed
₹1,856.71Cr2Trading Goods - Purchase
₹2.61CrPrice Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹1,133
52W Low
₹480
Volume101.08K
Avg VolumeN/A
Beta1.10
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
542.88x
Valuation
P/B Ratio
4.49x
Valuation
EPS
₹1.79
Valuation
Dividend Yield
0.00%
Valuation
ROE
1.34%
Profitability
ROCE
1.62%
Profitability
Revenue by Segment
Contribution & growth by business line
PharmaceuticalsRevenue split N/A
Geographical Revenue Split
Domestic vs international exposure
Domestic
19.9%
International
80.1%
Rest of the world80.1%
India19.9%
Strategic Relations
Collaborations, joint ventures & subsidiaries
S
SBD Laboratories
Italy
0.00% stakeS
Sintofarm SPA
Italy
0.00% stakeForensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.28x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
11.5%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.